Royal Bank Of Canada reaffirmed their buy rating on shares of Edwards Lifesciences Corporation (NYSE:EW) in a report issued on Friday. Royal Bank Of Canada currently has a $130.00 price objective on the medical research company’s stock.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Edwards Lifesciences Corporation from a buy rating to a hold rating in a research note on Thursday, May 18th. BidaskClub lowered shares of Edwards Lifesciences Corporation from a strong-buy rating to a buy rating in a research note on Wednesday, July 19th. Bank of America Corporation increased their price objective on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a buy rating in a research note on Thursday, July 27th. SunTrust Banks, Inc. increased their price objective on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a buy rating in a research note on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They issued a conviction-buy rating and a $138.00 price objective for the company. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Edwards Lifesciences Corporation currently has an average rating of Buy and a consensus target price of $121.13.

Edwards Lifesciences Corporation (EW) opened at 115.18 on Friday. The company has a market cap of $24.25 billion, a PE ratio of 34.93 and a beta of 0.63. The company’s 50-day moving average price is $117.20 and its 200-day moving average price is $104.28. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.76 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post $3.53 earnings per share for the current year.

WARNING: “Edwards Lifesciences Corporation (NYSE:EW) Rating Reiterated by Royal Bank Of Canada” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/edwards-lifesciences-corporation-nyseew-rating-reiterated-by-royal-bank-of-canada/1464982.html.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 34,120 shares of the firm’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $109.98, for a total value of $3,752,517.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 49,100 shares of the firm’s stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $109.71, for a total transaction of $5,386,761.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 184,951 shares of company stock valued at $20,780,242. Insiders own 2.13% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC increased its position in shares of Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the last quarter. YorkBridge Wealth Partners LLC purchased a new position in shares of Edwards Lifesciences Corporation during the first quarter valued at approximately $110,000. NEXT Financial Group Inc increased its position in shares of Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares during the last quarter. Cornerstone Advisors Inc. increased its position in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares during the last quarter. Finally, Alexandria Capital LLC increased its position in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the last quarter. 83.80% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.